Search

2024 AUG 22 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2024 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in obstetrics and gynecology. According to news reporting from the [...]

2024 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Breast Cancer have been published. According to news [...]

2024 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on breast cancer screening is now available. According to news reporting [...]

2024 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New study results on psammocarcinomas have been published. According to news reporting originating from [...]

The article discusses a comparative analysis of the drugs Endoxifen, Tamoxifen, and Fulvestrant in the context of breast cancer treatment. Through bioinformatics approaches, the study explores the mechanisms of action of these drugs, highlighting their effects on estrogen signaling, cell cycle pathways, apoptosis, and immune responses. The research suggests that advanced AI-driven methodologies can enhance the understanding of endocrine therapy mechanisms in breast cancer, potentially aiding in the selection of more effective therapies and the identification of drug-specific biomarkers. [Extracted from the article]

A recent study conducted by researchers at Fudan University Shanghai Cancer Center focused on the mechanisms of tamoxifen resistance in breast cancer. The study highlighted the role of long non-coding RNAs (lncRNAs) in mediating tamoxifen resistance through various molecular mechanisms. The researchers emphasized the potential clinical significance of lncRNAs as innovative therapeutic targets and prognostic biomarkers for breast cancer. This research sheds light on the complexities of endocrine resistance in breast cancer and offers insights into potential treatment strategies. [Extracted from the article]

A study conducted at New Mexico State University has used time-resolved flow cytometry (TRFC) to measure metabolic differences in estrogen receptor-positive breast cancer cells. The study found that differences in fluorescence lifetime were associated with sensitivity to the commonly prescribed therapeutic tamoxifen. Tamoxifen-resistant breast cancer cells were found to have increased utilization of glycolysis for energy production compared to tamoxifen-sensitive cells. This research is significant as it establishes a step towards developing a reliable screening technology for drug sensitivity in breast cancer cells. [Extracted from the article]

A study conducted by researchers at the Universidad Autonoma de Baja California in Mexicali, Mexico, has found that the natural compound auraptene can enhance the effectiveness of tamoxifen metabolites in treating chemoresistant estrogen receptor positive (ER+) breast cancer. Tamoxifen is commonly used in hormone treatment for ER+ breast cancer, but resistance can develop. The researchers developed a tamoxifen-resistant cell variant and aimed to reverse its resistance by incorporating auraptene. The combination of auraptene and tamoxifen metabolites successfully sensitized the chemoresistant cells, suggesting a potential pharmacologic strategy for treating resistant ER+ breast cancer. [Extracted from the article]

A study conducted by researchers at Islamic Azad University in Tehran, Iran, explored the use of carbon nanotubes (CNTs) loaded with tamoxifen as a potential treatment for breast cancer. The study found that the combination of tamoxifen and CNTs had a greater cytotoxic and apoptotic effect on breast cancer cells compared to tamoxifen alone. The researchers determined the IC50 values for both tamoxifen and tamoxifen-loaded CNTs and evaluated the expression of BAX and BCL-2 genes, as well as cell viability, using various assays. These findings suggest that CNTs could enhance the therapeutic response to anti-cancer drugs in breast cancer treatment. [Extracted from the article]

A recent study conducted at the University of Verona investigated the effects of low ozone concentrations on tamoxifen-treated breast cancer cells. The researchers found that low ozone concentrations did not have a cytoprotective effect on these cells, nor did they interfere with the effects of tamoxifen. This suggests that low ozone doses, which are increasingly used as a complementary treatment for oncological patients, do not confer drug resistance or reduce the efficacy of antitumor agents. While these findings were obtained in an in vitro model, they provide valuable insights into the potential impact of low ozone concentrations on breast cancer cells. [Extracted from the article]

Researchers at Xinxiang Medical University have released new data on siRNA libraries and their impact on breast cancer. The study found that over-activated estrogen receptor (ER) signaling is a major factor in luminal breast cancers, which can be managed with selective estrogen receptor modulators (SERMs) like tamoxifen. However, approximately 30-40% of ER+ breast cancer cases are recurrent after tamoxifen therapy. The researchers identified Ubiquitin-specific peptidase 36 (USP36) as a key deubiquitinase involved in ER signaling and breast cancer progression. Inhibiting USP36 combined with tamoxifen could potentially provide a new therapy for breast cancer. [Extracted from the article]

A recent study conducted by Harvard University examined the use of adjuvant ovarian function suppression (OFS) with oral endocrine therapy in premenopausal patients with hormone receptor-positive (HR+) breast cancer. The study aimed to identify a genomic biomarker that could predict which patients would benefit most from OFS-based treatment. The researchers used the Breast Cancer Index (BCI) to assess the predictive and prognostic performance of OFS in premenopausal women with HR+ breast cancer. The results showed that patients with BCI(H/I)-low tumors benefited more from OFS-containing endocrine therapy, suggesting that BCI(H/I)-low status could help identify patients who would benefit from more intensive treatment. [Extracted from the article]

A recent study conducted at the National Cancer Center Hospital investigated the efficacy and safety of combining palbociclib and tamoxifen in the treatment of hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. The study included 184 women who were randomly assigned to receive either palbociclib-tamoxifen or placebo-tamoxifen. The results showed that palbociclib-tamoxifen significantly improved progression-free survival (PFS) compared to tamoxifen alone. Although overall survival (OS) data is still immature, there was a trend favoring palbociclib-tamoxifen. The most common adverse event was neutropenia. This study provides valuable insights into the potential benefits of combining palbociclib and tamoxifen in the treatment of advanced breast cancer. [Extracted from the article]

A clinical trial, NCT06557057, has been launched to assess the impact of hormone-directed treatment for breast cancer on glucose metabolism. The study will compare the glucose homeostasis of women with hormone receptor positive breast cancer treated with aromatase inhibitors to that of healthy postmenopausal women and women treated with tamoxifen. Participants will undergo blood sample collection, glucose testing, and medical record reviews. The trial is currently recruiting participants and is expected to be completed by December 2025. [Extracted from the article]

A recent study conducted by researchers at Autonomous University Baja California in Mexicali, Mexico, has found that high levels of low-density lipoproteins (LDL) in breast cancer patients may promote cancer progression and resistance to tamoxifen treatment. The study generated two resistant cellular variants of breast cancer cells and found that one variant showed a transition towards a triple-negative breast cancer phenotype, while the other variant showed only slight metabolic adaptations. The researchers suggest that the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) may play a role in these phenotypic differences. Further research is needed to explore the potential implications of these findings. [Extracted from the article]

A recent report from Duke University highlights new research on breast cancer treatment. The study focuses on the role of the enzyme EZH2 in tamoxifen resistance, a major challenge in breast cancer therapy. The researchers found that EZH2 proteolysis targeting chimeras (PROTACs) effectively inhibited the growth of breast cancer cells, including those with acquired tamoxifen resistance. These findings suggest that EZH2-targeted PROTACs could be a promising avenue for future breast cancer treatment, particularly in cases of tamoxifen resistance. The study was supported by the U.S. Department of Health & Human Services and the National Cancer Institute. [Extracted from the article]

2023 APR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in breast cancer. According to news reporting out of Warsaw, [...]

2023 APR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2023 APR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on breast cancer have been presented. According to news originating from Amsterdam, [...]

2023 APR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on breast cancer have been published. According to news reporting from [...]

2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on breast cancer is now available. According to news reporting from [...]

2023 MAR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on breast cancer have been published. According to news originating from [...]

2023 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2023 JAN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New study results on medical case reports have been published. According to news originating [...]

2023 JAN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on breast cancer have been presented. According to news reporting out of [...]

A recent study conducted by researchers at Nicolaus Copernicus University in Torun, Poland, has explored the effects of tamoxifen, a selective estrogen receptor modulator (SERM), on breast cancer cell lines with different biological subtypes. The study found that tamoxifen derivatives, specifically 4-hydroxytamoxifen (4-HT), had a significant impact on DNA methylation patterns and the expression of TET3, a gene involved in epigenetic alterations. The findings suggest that targeting epigenetic modifications could be a promising approach for personalized anti-cancer therapy. This research provides new insights into the role of SERMs in breast cancer treatment and offers potential avenues for improving treatment outcomes. [Extracted from the article]

A recent study conducted in Osmaniye, Turkey compared the results of colposcopic biopsies in breast cancer patients and individuals who tested positive for HPV in cervix uteri cytological screenings. The study aimed to investigate the impact of tamoxifen treatment, an anti-estrogen drug used in breast cancer treatment, on histopathological changes. The study found that tamoxifen treatment did not lead to an increase in abnormal histological changes in the cervix uteri. The researchers concluded that gynecological examination and cervical cytological screening should be advised for all breast cancer cases. [Extracted from the article]

A recent study conducted at Linkoping University in Sweden examined the long-term outcomes of tamoxifen therapy in postmenopausal patients with early-stage breast cancer. The study found that patients with estrogen receptor positive (ER+) disease who received 5 years of tamoxifen treatment had significantly reduced breast cancer mortality compared to those who received 2 years of treatment. The benefits of prolonged tamoxifen therapy were particularly pronounced in patients with low ER levels or progesterone receptor negative (PR-) disease. However, there was no significant benefit observed in patients with high ER levels or progesterone receptor positive (PR+) tumors. This research provides valuable insights into the effectiveness of tamoxifen therapy for different subgroups of breast cancer patients. [Extracted from the article]

A recent study conducted by researchers at the University of Utah examined the population-level effect of two adjuvant therapies, tamoxifen and trastuzumab, on breast cancer recurrence. The study utilized a trend-in-trend pharmacoepidemiologic study design and analyzed data from the Danish Breast Cancer Group clinical database. The results showed that the introduction of tamoxifen for premenopausal women with estrogen receptor-positive breast cancer in 1999 led to a significant decrease in the risk of recurrence. However, the association between tamoxifen use and recurrence from its introduction in 1982 was imprecise and inconsistent with prior knowledge from clinical trials. The introduction of trastuzumab in 2007 also showed a consistent but imprecise effect on recurrence. The study highlights the potential of novel pharmacoepidemiologic analytic designs in evaluating the effectiveness of therapeutic advancements in a population-based setting. [Extracted from the article]

A recent study conducted by researchers at Lund University in Sweden examined the use of hormone receptor mRNA and protein levels as predictors of the benefits of tamoxifen therapy in premenopausal breast cancer patients. The study compared different methods of determining hormone receptor status and found that cytosol-based methods, immunohistochemistry (IHC), and gene expression (GEX) analysis all performed equally well in identifying patients who would benefit from tamoxifen. The researchers concluded that GEX data could potentially be used to guide adjuvant tamoxifen therapy. This study was supported by various funding sources, including Cancerfonden and Anna Och Edwin Bergers Stiftelse. [Extracted from the article]

A recent study conducted at the University of Notre Dame has explored the potential of using aquaporin inhibitors as a treatment for breast cancer. Aquaporins (AQPs) have been found to contribute to the progression and metastasis of breast cancer. The study evaluated two AQP inhibitors, Auphen and Z433927330, and found that Auphen treatment extended overall survival and increased the responsiveness of breast cancer cells to chemotherapy and endocrine treatment. However, further refinement and optimization of AQP inhibition are needed to overcome endocrine therapy resistance. This research highlights AQPs as potential therapeutic targets for breast cancer treatment. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential mechanisms behind therapeutic resistance to tamoxifen in ER alpha-positive breast cancer patients. The study suggests that the loss of the tumor suppressor FRMD8 may contribute to tamoxifen resistance by reducing the levels of ER alpha, a hormone receptor involved in breast cancer. The researchers found that FRMD8 deficiency in mice accelerated tumor growth and conferred tamoxifen resistance. They also discovered that FRMD8 interacts with both ER alpha and UBE3A, a protein involved in protein degradation, and disrupts the interaction between UBE3A and ER alpha, leading to decreased ER alpha levels. The study suggests that FRMD8 may be an important regulator of ER alpha and could potentially impact therapeutic sensitivity to tamoxifen in breast cancer patients. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Xavier University of Louisiana has provided new insights into breast cancer. The study focused on the role of CK2, a protein kinase, in regulating the expression and function of estrogen receptors (ERa) in breast cancer cells. The researchers found that a clinical stage CK2 inhibitor called CX-4945 disrupted the interaction between ERa and HSP90, a molecular chaperone, leading to the degradation of ERa proteins. This discovery suggests that CX-4945 could be a potential therapeutic strategy for treating both tamoxifen-sensitive and tamoxifen-resistant breast cancer. [Extracted from the article]

A study conducted by researchers at Southern Medical University in Guangdong, China, explored the potential of a recently synthesized derivative of podophyllotoxin (PPT) called bromosulfonamidine amino-PPT (BSAPPT) in treating tamoxifen-resistant breast cancer. The study found that BSAPPT inhibited the proliferation of tamoxifen-resistant breast cancer cells and induced apoptosis, effectively halting the malignant progression of the disease. These findings suggest that BSAPPT may hold promise as a therapeutic agent for the treatment of tamoxifen-resistant breast cancer. The study has been peer-reviewed and published in Oncology Letters. [Extracted from the article]

A recent study conducted at Guang'anmen Hospital in Beijing, China, has found that artemisinin, a compound derived from the herb Artemisia annua, may be effective in reversing tamoxifen resistance in estrogen receptor-positive breast cancer. Tamoxifen is commonly used as a treatment for hormone receptor-positive breast cancer, but drug resistance often leads to recurrence. The study used bioinformatics analysis and experimental validation to identify key genes and pathways involved in tamoxifen resistance and found that artemisinin could reduce migratory and drug resistance of tamoxifen-resistant cells. These findings suggest that artemisinin could potentially be used as a new therapy to enhance patient quality of life and reduce recurrence rates in breast cancer. [Extracted from the article]

The patent application by Myriad International GmbH outlines a method for predicting the risk of breast cancer recurrence in patients receiving endocrine therapy. By analyzing the expression levels of certain genes in tumor samples and combining them, a combined score is generated to determine the patient's prognosis. This method aims to improve treatment decision-making, especially for patients with intermediate risk based on standard clinical parameters. The application provides comprehensive information on the genes and techniques used in the method, offering a potential tool to optimize treatment decisions and avoid unnecessary treatments. [Extracted from the article]

Researchers from the Department of Pathology have published a case report and literature review on a rare case of a 15 cm giant endometrial polyp in a 58-year-old woman with a history of tamoxifen use. The polyp, which is a benign growth in the uterine cavity, presented with the uncommon symptom of constipation. The researchers concluded that this is the largest reported endometrial polyp to date. This information may be useful for individuals studying obstetrics and gynecology. [Extracted from the article]

A recent study conducted at the University Medical Center Regensburg in Germany explored the impact of the HER4 receptor on the growth and treatment of estrogen receptor-positive breast cancer. Using CRISPR/Cas9 technology, researchers generated stable HER4 knockout variants from breast cancer cell lines. The study found that HER4 affects the cellular response to tamoxifen and abemaciclib treatment, with increased sensitivity observed in MCF-7 cells upon HER4 knockout. Additionally, the study assessed tumor growth and immunological effects in humanized tumor mice and found that the presence of HER4 affects the efficacy of tamoxifen and abemaciclib treatment in different estrogen receptor-positive breast cancer cells. [Extracted from the article]

A recent study conducted by researchers at the Medical University of South Carolina has identified a potential new therapeutic target for tamoxifen-resistant estrogen receptor-positive (ER+) breast cancer. The study found that a long-noncoding RNA called LINC00152 contributes to tamoxifen resistance by inhibiting ferroptosis, a form of iron-mediated cell death. Inhibiting LINC00152 was shown to restore tamoxifen-dependent ferroptosis and sensitize breast cancer cells to the drug. The researchers suggest that targeting LINC00152 and its effectors could improve clinical outcomes for patients with refractory ER+ breast cancer. [Extracted from the article]

A recent report discusses research conducted by the National Institute of Pharmaceutical Education and Research Guwahati on the topic of breast cancer. The study focuses on the challenges posed by rapid tumor proliferation and nutrition deprivation in maintaining cellular protein homeostasis. The researchers investigated the influence of tamoxifen, a commonly used therapeutic molecule, on cellular adaptation to endoplasmic reticulum stress during metabolic stress in breast cancer cells. The findings suggest that tamoxifen modulates endoplasmic reticulum stress by inducing a specialized autophagy process called ER-phagy through AMPK activation, potentially supporting breast cancer cell survival during nutrition deprivation conditions. [Extracted from the article]

A recent study conducted at Al Zaytoonah University in Jordan explored the metabolic changes in tamoxifen-resistant breast cancer cell lines. The researchers used metabolic profiling and gene expression analysis to identify potential biomarkers of resistance and understand the underlying molecular mechanisms. The study found that tamoxifen-resistant cells exhibited increased levels of glutamine, taurine, glutathione, and xanthine, as well as decreased levels of certain amino acids. Additionally, the expression of genes encoding key enzymes involved in these metabolic pathways was altered. The findings provide insights into the development of resistance and may contribute to the development of new treatment strategies. [Extracted from the article]

A recent report discusses research findings on breast cancer from China Three Gorges University. The study focuses on estrogen receptor-positive (ER+) breast cancer, which poses a significant threat to women's health. The researchers discovered that a citrus polymethoxyflavones (PMFs)-rich hydrolysate, along with its major components nobiletin and 3-methoxynobiletin, can effectively degrade the ERa protein and inhibit the proliferation of ER+ breast cancer cells. Additionally, when combined with tamoxifen, the hydrolysate showed promising results in inhibiting cell proliferation and reducing tumor growth in mice. These findings suggest that citrus PMFs have potential applications in breast cancer treatment by targeting ERa protein degradation. [Extracted from the article]

A recent study conducted at the Medical University of South Carolina has identified a potential new therapeutic target for tamoxifen-resistant estrogen receptor-positive (ER+) breast cancer. The researchers found that a long-noncoding RNA called LINC00152 contributes to tamoxifen resistance by blocking a form of cell death called ferroptosis. By inhibiting LINC00152, the researchers were able to restore tamoxifen-dependent ferroptosis and sensitize the cancer cells to the drug. This discovery may lead to improved clinical outcomes for patients with refractory ER+ breast cancer. [Extracted from the article]